Cadrenal Therapeutics (CVKD) Fireside Chat

Jan 13, 2025

During this fireside chat we welcome Cadrenal Therapeutics (Nasdaq: CVKD). Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions.

This fireside chat was recorded during the Lytham Partners 2025 Investor Healthcare Summit.

Skip to content